NEURACAP
Sector ReportSep 28, 2026 · 22 pages · Free to read

Food Ingredients and Flavorings Sector Outlook — September 2026

A sector outlook on Food Ingredients and Flavorings, comparing valuation across specialty ingredient chemistry, packaged-food brands and adjacent operating models. Built for corporate development, strategy and board audiences assessing where growth and margin quality support premium valuation positioning.

Download PDFDownload PowerPoint

Key figures

12.8x
Sector median valuation
EV / EBITDA (CY2027E), rated names
15.6x
Specialty chemistry cohort median
EV / EBITDA (CY2027E)
10.2x
Packaged-food brand cohort median
EV / EBITDA (CY2027E)
20.3x
Highest disclosed precedent multiple
EV/EBITDA at announcement, LTM basis

Read the report

C:\Users\dawoo\OneDrive\Desktop\Deployments\neuracap_sector_reports_fable\Code\NeuraCap_Sector_Report_Pipeline_v2.1.0\ncsr\deck_kit\assets\logo_light_full.png

CONSUMER STAPLES › FOOD, BEVERAGE AND TOBACCO › FOOD INGREDIENTS AND FLAVORINGS

Food Ingredients and Flavorings: Value Splits by Mix

This report shows where market value sits across specialty ingredient chemistry, adjacent brand owners and other operating models.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E)

Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice

1

1 / 22

Executive summary

Food Ingredients and Flavorings splits into distinct economic models: specialty ingredient chemistry sits at 15.6x EV/EBITDA against 10.2x for packaged-food brand owners, a gap consistent with durable spec-in positions and application depth. Among rated peers, faster revenue growth and higher EBITDA margin travel with higher valuation, and names clearing both bars sit at the top of the range. Precedent transactions show disclosed multiples spanning 7.8x to 20.3x, indicating buyers price strategic fit and asset quality individually rather than paying a uniform sector multiple.

Key findings

  • Specialty ingredient chemistry trades above packaged-food brand owners on EV/EBITDA.
  • Faster revenue growth aligns with a higher forward valuation among rated peers.
  • Clearing both growth and margin bars separates the top and bottom of the range.
  • Precedent deal multiples span a wide range, reflecting asset-specific buyer conviction.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    CONSUMER STAPLES › FOOD, BEVERAGE AND TOBACCO › FOOD INGREDIENTS AND FLAVORINGS

    Cover page introducing the Food Ingredients and Flavorings sector outlook and its valuation basis.

    This report examines where market value sits across specialty ingredient chemistry, adjacent brand owners and other operating models within Food Ingredients and Flavorings. We anchor every multiple on EV/EBITDA (CY2027E) as of September 28, 2026.

    Everything on this page

    CONSUMER STAPLES › FOOD, BEVERAGE AND TOBACCO › FOOD INGREDIENTS AND FLAVORINGS Food Ingredients and Flavorings: Value Splits by Mix This report shows where market value sits across specialty ingredient chemistry, adjacent brand owners and other operating models. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    Contents page listing the report's five numbered sections plus the appendix.

    The report runs five sections plus an appendix: the bottom line, the landscape, valuation and situations, precedent transactions and strategic implications. We front-load the conclusion in Section 01 so a reader who stops there still leaves with the full argument.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Capability and Earnings Quality Separate the Market 02 The Landscape The Sector Label Spans Businesses with Different Economics 03 Valuation & Situations The Premium End Reflects Durability Beyond the Forecast 04 Precedent Transactions Precedent Transactions Favour Buyers with Asset-Specific Conviction 05 Strategic Implications Strengthen the Operating Proof Behind Mix, Margin and Retention 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Food Ingredients and Flavorings Split Between Specialty Chemistry and Adjacent Brand Models

    This page lays out the report's core finding that valuation splits between specialty chemistry and adjacent brand models.

    Our primary valuation basis is EV/EBITDA on CY2027E consensus, covering the companies that clear the platform's plausibility gates. Specialty ingredient chemistry sits toward the top of that range, while adjacent brand and other operating models sit lower. Growth and margin further separate the peer set, and precedent transactions show buyers pricing strategic fit across a wide span. So the sector label alone tells a client little — business model, growth and margin tell most of the story.

    Everything on this page

    01 · THE BOTTOM LINE Food Ingredients and Flavorings Split Between Specialty Chemistry and Adjacent Brand Models The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Specialty Chemistry Sits Above Packaged-Food Brands The four specialty chemistry names with estimates sit at 15.6x, against 10.2x for the three packaged-food brand owners with estimates. The difference is consistent with greater value being placed on specified solutions, application capability and spec-in positions. 2 Faster Growth Travels with a Higher Forward Valuation Among eight names with estimates, the four at or above 4% revenue growth sit at 12.9x; the four below sit at 10.9x. The observed premium supports close attention to brief wins, formulation mix and customer adoption. 3 The Names Clearing Both the Growth and the Margin Bar Sit at the Top of the Valuation Range Among eight names with estimates, the three above both the growth and 18% margin lines sit at 15.0x, while the three below both sit at 6.9x. Price/mix, fixed-cost absorption and raw-material recovery remain central to that positioning. 4 Precedent Transactions Leave Room for Asset-Specific Conviction Disclosed EV / EBITDA in the transaction record spans 7.8x to 20.3x. That range suggests buyers distinguish carefully among capability depth, earnings quality and strategic fit. 12.8x Sector median EV/EBITDA CY2027E consensus · 8 rated of 12 companies 16.8x Premium end EV/EBITDA vs 5.8x at the discount end top quartile (n=2) against bottom quartile (n=2) on EV/EBITDA — the spread the report explains 15 Transactions with disclosed terms 42 recorded in this tier · 1 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    Divider introducing the second section on how the sector label spans different business economics.

    The Food Ingredients and Flavorings label covers specified ingredient solutions, packaged-food brands and adjacent operating models with different economics. The next pages map where each sits on valuation.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE The Sector Label Spans Businesses with Different Economics Specified ingredient solutions sit beside packaged-food brands and adjacent operating models. 02 of 06 Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Specified Ingredient Chemistry Sits Toward the Upper End of the Valuation Range

    This page groups the approved companies by business segment and shows median EV/EBITDA (CY2027E) by group.

    Grouping the approved universe by segment, specified ingredient chemistry sits toward the upper end of the valuation range. Group medians are drawn only on rated names, so the comparison reflects consensus estimates rather than a full-universe average. This positioning is consistent with the market placing incremental value on specified, spec-in solutions over more commoditized models. So for a client assessing where to allocate capital, the segment view narrows the search to where premium valuation already concentrates.

    Everything on this page

    02 · MARKET MAP Specified Ingredient Chemistry Sits Toward the Upper End of the Valuation Range 12 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 ADJACENT: PACKAGED FOOD BRAND OWNERS (FORMULATION CUSTOMERS) 5 cos median 10.2x The Kraft Heinz (KHC) Nomad Foods (NOMD) Westrock Coffee (WEST) The Hain (HAIN) Beyond Meat (BYND) These formulation customers provide an offtake-side view shaped by brand economics, procurement pressure and category demand. SPECIALTY FOOD INGREDIENT CHEMISTRY — COLORS, ENZYMES AND TEXTURANTS 4 cos median 15.6x International (IFF) Sensient (SXT) Balchem (BCPC) Alto Ingredients (ALTO) These businesses compete through formulation know-how, application support, qualification barriers and specified performance. ADJACENT MODELS 3 cos 10.7x · 1 rated Keurig Dr Pepper (KDP) Domino's Pizza (DPZ) Vital Farms (VITL) These names broaden the market view across beverages, foodservice and primary sourcing models.

  6. 06
    02 · LANDSCAPE

    Valuations Track the Business Model More Closely than the Shared Sector Label

    This page shows that valuation tracks business model more closely than the shared sector label across the approved universe.

    Segment-level EV/EBITDA (CY2027E) medians show valuation clustering by what a company actually does, not by its sector classification. Full company-level detail sits in the appendix for any name a client wants to trace. This reinforces that peer selection should start with business model, not sector label. So comparisons built on sector alone risk mismatching targets against the wrong reference set.

    Everything on this page

    02 · LANDSCAPE Valuations Track the Business Model More Closely than the Shared Sector Label Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Adjacent: packaged food brand owners (formulation customers) 5 42% 10.2x The Kraft Heinz Company (KHC) · Nomad Foods Limited (NOMD) · +3 more Brands anchor customer demand. Packaged-food owners represent the customer side of formulation and reformulation. Their economics reflect brand strength, category volume and procurement choices as much as ingredient capability. Specialty food ingredient chemistry — colors, enzymes and texturants 4 33% 15.6x International Flavors & Fragrances Inc. (IFF) · Sensient Technologies Corporation (SXT) · +2 more Technical capability supports differentiation. Color, enzyme and texturant suppliers compete through spec-in positions, application labs and co-creation. Qualification cycles and on-label approvals can support durable customer relationships. Adjacent models 3 25% 10.7x n=1 Keurig Dr Pepper Inc. (KDP) · Domino's Pizza, Inc. (DPZ) · +1 more Adjacent economics widen the frame. Beverage, foodservice and sourcing models expose different demand, capital and margin structures. They are useful context but require care when compared with specialist ingredient houses.

  7. 07
    SECTION 03

    03

    Divider introducing the section on public market valuation and what sits behind the premium end of the range.

    The premium end of the valuation range reflects durability that persists even after expected growth is already credited. The following pages unpack what separates the top of the range from the bottom.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Premium End Reflects Durability Beyond the Forecast The forward valuation range remains wide after expected growth is already credited. 03 of 06 Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    The Top of the Valuation Range Trades Well Clear of the Bottom, Even Once Forecast Growth Is Credited

    This page ranks all rated companies by EV/EBITDA (CY2027E) against a sector median of 12.8x.

    Sorted descending, the top of the valuation range trades well clear of the bottom, even once forecast growth is credited into the multiple. The sector median sits at 12.8x, with tier zones cut at the rated set's quartiles. Every multiple on this page sits on the same EV/EBITDA (CY2027E) basis, so the spread is comparable across names. So the width of that range is itself information: it signals the market is discriminating between names beyond growth alone.

    Everything on this page

    03 · PUBLIC MARKET VALUATION The Top of the Valuation Range Trades Well Clear of the Bottom, Even Once Forecast Growth Is Credited EV / EBITDA (CY2027E) · all 8 rated companies, sorted descending · sector median 12.8x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 16.8x CORE · median 12.8x DISCOUNT · median 5.8x Sector median 12.8x WHAT SEPARATES THE TWO ENDS The forward gap remains wide. The premium end sits at 16.8x against 5.8x at the discount end. Because the EV / EBITDA lens is forward, expected growth is already credited; the remaining gap points to differing views of earnings durability. Specified capability supports confidence. Application depth, spec-in positions and qualification barriers can help buyers assess the resilience of revenue and margin through customer and input cycles. Mix quality sharpens the test. The key distinction is how much earnings come from formulated solutions versus commodity or tolling exposure, and how reliably price/mix protects the base.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 18% Margin Line Carry 15.6x Against 8.5x Below It

    This page splits the rated cohort by growth and by margin to show what separates high multiples from low ones.

    Names above the 18% margin line carry a median 15.6x against 8.5x below it, a split drawn on matched cohorts of rated names. Growth cohorts show a similar, if narrower, separation. These are cohort medians on rated names with the required estimates, and the reading is an association rather than a claim about what causes the gap. So for a client benchmarking a target or a portfolio, margin quality looks like the sharper of the two dividing lines.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 18% Margin Line Carry 15.6x Against 8.5x Below It Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=4; slower n=4; higher-margin n=4; lower-margin n=4). Driver readings are NeuraCap views on the supplied data — association, not causation. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 4% · EBITDA-margin split at 18% Growth Separates the Two Valuation Groups Among eight names with estimates, the four at or above 4% growth sit at 12.9x, compared with 10.9x for the four below. This is an observed association, not evidence that growth alone accounts for the difference. Margin Adds an Important Second Test The names clearing both growth and profitability thresholds occupy a different valuation position from those clearing neither. Price/mix, plant utilisation and pass-through recovery help frame the quality of that margin. Commercial Proof Sits Inside the Pipeline Brief wins, vitality from recent formulations and share of key-account spend indicate whether current growth rests on repeatable co-creation and spec-in activity. Durability Depends on Revenue Quality Qualification barriers, customer retention and solutions mix can support resilience. Commodity exposure, crop volatility and customer concentration can weaken it.

  10. 10
    03 · SITUATION MAP

    Higher Multiples Sit on Both Sides of the Growth Line

    This page cross-cuts the rated names by valuation versus the sector median and by growth versus the covered median.

    Higher multiples appear on both sides of the growth line, so growth alone does not explain who sits above the sector median. The boundaries shown are the cohort's own medians, and the page characterises situations rather than recommending any transaction. So a name's valuation position needs its own explanation, not just a growth story.

    Everything on this page

    03 · SITUATION MAP Higher Multiples Sit on Both Sides of the Growth Line Cut on EV / EBITDA vs the sector median (12.8x) (rows) and revenue growth vs the covered median (4%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium with Momentum Above-median multiple · above-median revenue growth 2 names Sensient Technologies Corporation (SXT) · Balchem Corp (BCPC) These names combine above-line growth with an above-line multiple. Their position supports testing whether brief wins, customer adoption and margin quality can sustain the current standing. Premium Without Momentum Above-median multiple · below-median revenue growth 2 names International Flavors & Fragrances Inc. (IFF) · The Hain Celestial Group, Inc. (HAIN) These names hold an above-line multiple despite below-line growth. The valuation may reflect margin durability, portfolio quality or confidence in recovery, which makes retention and mix central tests. Growth Awaiting Recognition Below-median multiple · above-median revenue growth 2 names Keurig Dr Pepper Inc. (KDP) · Westrock Coffee Company, LLC (WEST) These names show above-line growth while valuation remains below the sector reference. The commercial question is whether growth converts into durable margin and higher-quality mix. Rebuild Both Dimensions Below-median multiple · below-median revenue growth 2 names Nomad Foods Limited (NOMD) · Alto Ingredients, Inc. (ALTO) These names sit below both the growth and valuation references. Improvement depends on operating evidence around mix, cost absorption, pricing and customer retention.

  11. 11
    03 · GROWTH VS PROFITABILITY

    Clearing Both Growth and Margin Bars Separates the Valuation Field

    This page plots growth against margin for companies with both estimates and shows median EV/EBITDA by quadrant.

    Cuts sit at the covered medians of 4% growth and 18% margin. Clearing both growth and margin bars separates the valuation field more sharply than either measure alone. Quadrant medians are drawn on names with a meaningful multiple in each cell. So the combination of growth and margin, not either alone, does the most work in explaining where a name sits.

    Everything on this page

    03 · GROWTH VS PROFITABILITY Clearing Both Growth and Margin Bars Separates the Valuation Field Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2026E, y-axis) · 8 companies with both estimates · cuts at the covered medians (4% growth, 18% margin) · median EV/EBITDA per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/EBITDA (balanced n=3; margin-only n=1; growth-only n=1; neither n=3). Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 -5% 0% 5% 10% 15% 5% 10% 15% 20% 25% MARGIN ONLY median 16.2x BALANCED median 15.0x NEITHER median 6.9x GROWTH ONLY median 10.2x HAIN ALTO IFF NOMD BCPC WEST SXT KDP x: revenue growth (CY2027E) · y: EBITDA margin (CY2026E) HOW TO READ THIS Among eight names with estimates, three clear both the growth and 18% margin lines and sit at 15.0x; Balchem Corp (BCPC), Sensient Technologies Corporation (SXT) and Keurig Dr Pepper Inc. (KDP) are in this group. One name clears only the margin line and sits at 16.2x. One clears only the growth line and sits at 10.2x. The three below both lines sit at 6.9x, showing the lower valuation position associated with neither threshold being met. The neither median rests on 3 names and is lifted by HAIN at 14.9x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 0 of 8 names clear it.

  12. 12
    03 · THE AGENDA

    A Company's Place in the Valuation Range Moves with Its Growth and Margin Record

    This page frames the questions an owner or acquirer should resolve given how growth and margin move valuation position.

    A company's place in the valuation range moves with its growth and margin record, based on the cohort data shown earlier. This is NeuraCap advisory judgment framed as questions to resolve, not a recommendation to buy or sell any security. So for a client planning the next twelve months, these questions set the agenda for where to focus commercial and operating attention.

    Everything on this page

    03 · THE AGENDA A Company's Place in the Valuation Range Moves with Its Growth and Margin Record NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Move Further into Specified Solutions Prioritise formulation work where qualification, on-label approval and organoleptic performance support durable customer positions. What changes the answer: Brief wins convert into repeat orders without giving back price/mix. Build Breadth Around Customer Briefs Add capabilities that let application teams solve more of a customer’s taste, color, texture and nutrition requirements. What changes the answer: Cross-capability briefs raise share of key-account spend and shorten the path to launch. Protect Margin Through the Cycle Tighten pass-through mechanics, campaign planning and fixed-cost absorption while reducing exposure to volatile commodity streams. What changes the answer: Margin holds as input costs, customer inventories and plant utilisation change. Use Capital Where Capability Compounds Compare internal build, partnership and acquisition routes for application labs, encapsulation, natural colors and regional supply assurance. What changes the answer: The chosen route clears customer qualification faster and supports repeatable commercial returns.

  13. 13
    SECTION 04

    04

    Divider introducing the section on precedent transactions and what they reveal about buyer conviction.

    The transaction record spans platform acquisitions, capability additions and portfolio reshaping. The following pages show precedent multiples favour buyers with asset-specific conviction over a uniform sector price.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Favour Buyers with Asset-Specific Conviction The transaction record spans platform acquisitions, capability additions and portfolio reshaping. 04 of 06 Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    Precedent Transactions Suggest Buyers Price Strategic Fit Across a Wide Range

    This page walks through a disclosed-terms transaction as a case study, with the complete list held in the appendix.

    Disclosed multiples are based on LTM financials at announcement and are not directly comparable to the CY2027E public basis; no spread is claimed between them. Some recorded transactions carry data-quality flags, and a number of recorded transactions without a disclosed value or multiple are held in the companion workbook rather than shown here. The case study read on why the deal happened is a NeuraCap view of the recorded evidence. So the precedent record still supports asset-specific comparisons even where a clean sector-wide multiple isn't available.

    Everything on this page

    04 · DEAL CASE STUDIES Precedent Transactions Suggest Buyers Price Strategic Fit Across a Wide Range 1 of 15 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 52 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; no evidence record); figures are shown as recorded in the filing. 27 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Feb-2026 $1.1B 2786694 Alberta Ltd. 2786694 Alberta Ltd. agreed to acquire SunOpta Inc. as a complete operating platform. EV / LTM revenue 1.4x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests conviction in SunOpta Inc. as a standalone platform rather than a disclosed capability bolt-on. The buyer’s recorded identity does not support a more specific operating rationale. HOW THE TARGET WAS VALUED SunOpta Inc. was valued at $1.1B and 1.4x EV / Revenue. This is a revenue benchmark and should be read separately from the forward EV / EBITDA lens used for the peer set.

  15. 15
    SECTION 05

    05

    Divider introducing the section on strategic implications for owners, management teams and boards.

    The practical agenda is to deepen specified solutions while protecting the earnings base. The next page turns the data into questions for the next twelve months.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Strengthen the Operating Proof Behind Mix, Margin and Retention The practical agenda is to deepen specified solutions while protecting the earnings base. 05 of 06 Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    Where Revenue Is Durable and Margin Defensible, Valuations Sit Nearer the Top of the Range

    This page argues that valuations sit nearer the top of the range where revenue is durable and margin defensible.

    Where revenue is durable and margin is defensible, valuations sit nearer the top of the range, based on the analysis built through this report. These are NeuraCap views grounded in the cohort data, framed as observations rather than recommendations. So for owners, management teams and boards, the practical agenda is to strengthen the operating proof behind mix, margin and retention over the next twelve months.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Where Revenue Is Durable and Margin Defensible, Valuations Sit Nearer the Top of the Range NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Make Solutions Mix the Operating Priority Shift commercial attention toward specified formulations, co-creation and repeat brief wins. Protect the customer positions where qualification and on-label approval make replacement harder. FOR MANAGEMENT TEAMS Link Growth to Margin Quality Separate volume recovery from price/mix and new-formulation adoption. Align plant loading, raw-material recovery and account choices with the earnings base the market can sustain. FOR BOARDS Allocate Capital Around Capability Gaps Test build-versus-buy choices against customer access, qualification time, technical depth and regional supply assurance. Favour moves that strengthen the solutions core without adding unmanaged capital drag.

  17. 17
    SECTION 06

    06

    Divider introducing the appendix covering the full comparables universe, methodology and sources.

    The appendix carries comparables detail behind every figure in the body, the valuation basis and where each underlying disclosure lives. Use it to trace any figure a client wants to check.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier

    This page lists rated and unrated companies on EV/EBITDA (CY2027E), grouped by valuation tier.

    Teal shading marks a multiple above the sector median of 12.8x; amber marks below it. All rated rows sit in this appendix and in the companion workbook, which carries the complete field set, and names without an eligible multiple are listed separately. So this is the full comparables record behind every valuation claim made earlier in the report.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (12.8x); amber marks below · 8 rated companies; 4 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 8 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥15.3x · median 16.8x · 2 companies Balchem Corp BCPC Specialty food ingredient chemistry — colors, enzymes… $5.6B 17.4x 6% 27% 32 International Flavors & Fragrances Inc. IFF Specialty food ingredient chemistry — colors, enzymes… $27.7B 16.2x 1% 20% 23 CORE — 9.3x–15.3x · median 12.8x · 4 companies Sensient Technologies Corporation SXT Specialty food ingredient chemistry — colors, enzymes… $6.2B 15.0x 13% 20% 33 The Hain Celestial Group, Inc. HAIN Adjacent: packaged food brand owners (formulation… $596M 14.9x -5% 8% -1 Keurig Dr Pepper Inc. KDP Adjacent: branded non-alcoholic beverages (ingredient… $77.8B 10.7x 14% 24% 38 Westrock Coffee Company, LLC WEST Adjacent: packaged food brand owners (formulation… $1.3B 10.2x 8% 8% 18 DISCOUNT — <9.3x · median 5.8x · 2 companies Nomad Foods Limited NOMD Adjacent: packaged food brand owners (formulation… $3.9B 6.9x 2% 16% 18 Alto Ingredients, Inc. ALTO Specialty food ingredient chemistry — colors, enzymes… $357M 4.7x 0% 7% 8

  19. 19
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This page lists the first tier of disclosed-terms precedent transactions, newest first.

    This tier of transactions carries disclosed terms, with multiples on LTM financials at announcement where disclosed. Deal values link to the underlying filing for any transaction a client wants to open. These multiples are not directly comparable to the CY2027E public basis, and no spread is claimed between the two.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 15 transactions with disclosed terms in this tier (42 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 52 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; no evidence record); figures are shown as recorded in the filing. 27 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters May-2026 CVC Capital Partners → Food Ingredients business (unit of Food Ingredients business segment) $4.3B n/a n/a CVC Capital Partners agreed to acquire Food Ingredients business (unit of Food Ingredients business segment). The transaction highlights continuing interest in separable ingredient operations. Feb-2026 2786694 Alberta Ltd. → SunOpta Inc. $1.1B 1.4x n/a 2786694 Alberta Ltd. agreed to acquire SunOpta Inc. The transaction provides a recent benchmark for a complete operating platform. Jan-2023 Irca S.p.A. → Kerry Group plc n/a n/a 12.2x Irca S.p.A. agreed to acquire Kerry Group plc. The pairing suggests interest in extending an established ingredient offering. Oct-2022 Orkla Food Ingredients → Denali Ingredients n/a n/a 13.9x Orkla Food Ingredients agreed to acquire Denali Ingredients. The transaction suggests a strategic fit between an ingredient platform and an adjacent capability. Jun-2022 Horizon Therapeutics Plc → Natra S.A. n/a 8.3x n/a Horizon Therapeutics Plc agreed to acquire Natra S.A. The disclosed valuation provides a transaction reference, while the strategic fit should be assessed on the recorded parties. Dec-2019 International Flavors & Fragrances Inc. → DuPont Nutrition & Biosciences, Inc. $45.4B n/a n/a International Flavors & Fragrances Inc. (IFF) agreed to acquire DuPont Nutrition & Biosciences, Inc. The combination brought flavor, nutrition and bioscience capabilities into a broader platform. Dec-2019 Act II Global Acquisition Corp. → Whole Earth Brands (Merisant Co. and MAFCO Worldwide) n/a n/a 8.2x Act II Global Acquisition Corp. agreed to acquire Whole Earth Brands (Merisant Co. and MAFCO Worldwide). The transaction connected a public acquisition vehicle with a branded sweetener platform. Oct-2019 One Rock Capital Partners → Innophos Holdings, Inc. n/a n/a 7.8x One Rock Capital Partners agreed to acquire Innophos Holdings, Inc. The transaction is consistent with sponsor interest in technical, application-oriented businesses. May-2018 IFF → Frutarom n/a n/a 20.3x International Flavors & Fragrances Inc. (IFF) agreed to acquire Frutarom. The combination suggests strategic interest in a broader flavor and ingredient offering.

  20. 20
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This page continues the list of disclosed-terms precedent transactions, newest first.

    The remaining disclosed-terms transactions in this tier complete the record shown on the prior page. As before, multiples are read on LTM financials at announcement and are not directly comparable to the CY2027E public basis. So the companion workbook holds the transactions with neither a disclosed value nor a multiple.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 15 transactions with disclosed terms in this tier (42 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 52 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; no evidence record); figures are shown as recorded in the filing. 27 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Mar-2018 Givaudan → Naturex n/a n/a 22.8x Dec-2017 Nestlé S.A. → Atrium Innovations Inc. n/a n/a 14.0x Sep-2016 B&G Foods, Inc. → ACH Food Companies, Inc. (spices business) n/a n/a 9.4x Value shown as recorded in the filing; deal value unit unresolved. Aug-2016 Investors Group Inc. → Vitaco Holdings Limited n/a n/a 14.7x Dec-2012 Univar Inc. → Mangablend, Inc. n/a n/a 7.9x Dec-2010 Royal DSM N.V. → Martek Biosciences Corporation n/a 8.8x 8.8x

  21. 21
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This page documents the report's sources, assumptions and data-quality treatment.

    Every figure in this report links to the record it was taken from; where no link exists, the appendix names the source and the basis on which it was read. This page is where a client can check exclusion rules, the plausibility gates applied to multiples, and how segments were classified. So use it to verify any number before it feeds into an internal analysis.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Food Ingredients and Flavorings and it clears the coverage gate with 8 of 12 companies (67%). EV / Revenue, P / E are carried as a cross-check. The set earns: 8 of the 9 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 17 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 485 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (484) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  22. 22

    Higher Forward Valuations Sit with Growth, Margin and Specified-Solutions Quality.

    Closing page restating that higher forward valuations sit with growth, margin and specified-solutions quality.

    Higher forward valuations sit with growth, margin and specified-solutions quality across this peer set. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace further.

    Everything on this page

    Higher Forward Valuations Sit with Growth, Margin and Specified-Solutions Quality. NeuraCap AI — Food Ingredients and Flavorings Coverage September 2026 · Prepared by NeuraCap AI · Confidential Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22

Sources and methodology

This report covers Food Ingredients and Flavorings (Consumer Staples › Food, Beverage and Tobacco › Food Ingredients and Flavorings) with market data and consensus estimates as of September 28, 2026. The company universe is the 12 listed companies whose core business is Food Ingredients and Flavorings according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Alto Ingredients, Inc. (ALTO), Balchem Corp (BCPC), Beyond Meat, Inc. (BYND), Domino's Pizza, Inc. (DPZ), The Hain Celestial Group, Inc. (HAIN), International Flavors & Fragrances Inc. (IFF), Keurig Dr Pepper Inc. (KDP), The Kraft Heinz Company (KHC), Nomad Foods Limited (NOMD), Sensient Technologies Corporation (SXT), Vital Farms, Inc. (VITL), Westrock Coffee Company, LLC (WEST). The market map groups them by business vertical — Adjacent: packaged food brand owners (formulation customers): 5 companies (KHC, NOMD, WEST, HAIN, BYND); Specialty food ingredient chemistry — colors, enzymes and texturants: 4 companies (IFF, SXT, BCPC, ALTO); Adjacent models: 3 companies (KDP, DPZ, VITL). 8 of the 12 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Food Ingredients and Flavorings (Consumer Staples › Food, Beverage and Tobacco › Food Ingredients and Flavorings) with market data and consensus estimates as of September 28, 2026. The company universe is the 12 listed companies whose core business is Food Ingredients and Flavorings according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Alto Ingredients, Inc. (ALTO), Balchem Corp (BCPC), Beyond Meat, Inc. (BYND), Domino's Pizza, Inc. (DPZ), The Hain Celestial Group, Inc. (HAIN), International Flavors & Fragrances Inc. (IFF), Keurig Dr Pepper Inc. (KDP), The Kraft Heinz Company (KHC), Nomad Foods Limited (NOMD), Sensient Technologies Corporation (SXT), Vital Farms, Inc. (VITL), Westrock Coffee Company, LLC (WEST). The market map groups them by business vertical — Adjacent: packaged food brand owners (formulation customers): 5 companies (KHC, NOMD, WEST, HAIN, BYND); Specialty food ingredient chemistry — colors, enzymes and texturants: 4 companies (IFF, SXT, BCPC, ALTO); Adjacent models: 3 companies (KDP, DPZ, VITL). 8 of the 12 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

17 records failed a validation gate and never feed a statistic in this report (1 excluded from universe; 16 excluded from aggregate). Each exclusion, with its reason: INGR — The ticker INGR carries a preferred, warrant or unit suffix and the security name gives no sign of an operating company (effect: excluded from universe) · ALTO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BYND — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BYND — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BYND — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BYND — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BYND — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BYND — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BYND — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HAIN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HAIN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · IFF — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · KHC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · VITL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · WEST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · WEST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · WEST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)

Primary valuation basis and how it was chosen

Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Food Ingredients and Flavorings and it clears the coverage gate with 8 of 12 companies (67%). EV / Revenue, P / E are carried as a cross-check. The set earns: 8 of the 9 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 8 of 12 companies; EV / rEVenue: 12 of 12 companies; P/E: 11 of 12 companies. 1 company shows a non-meaningful EV / EBITDA denominator and is excluded from that statistic. 1 company shows a non-meaningful P / E denominator and is excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥15.3x, Core 9.3x–15.3x, Discount <9.3x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 12.8x = median(ev_ebitda CY2027E) (8 rated companies) · 16.8x = median(ev_ebitda CY2027E) within Premium tier (n=2) · 12.8x = median(ev_ebitda CY2027E) within Core tier (n=4) · 5.8x = median(ev_ebitda CY2027E) within Discount tier (n=2) · 12.9x = median(ev_ebitda CY2027E) | growth ≥ 4% (n=4) · 10.9x = median(ev_ebitda CY2027E) | growth < 4% (n=4) · 15.6x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 18% (n=4) · 8.5x = median(ev_ebitda CY2027E) | EBITDA margin < 18% (n=4) · 20% = median Rule of 40 score (revenue growth + EBITDA margin) (n=8) · 15.0x = median(ev_ebitda CY2027E) within balanced quadrant (n=3) · 16.2x = median(ev_ebitda CY2027E) within marginOnly quadrant (n=1) · 10.2x = median(ev_ebitda CY2027E) within growthOnly quadrant (n=1) · 6.9x = median(ev_ebitda CY2027E) within neither quadrant (n=3) · 14.9x = ev_ebitda CY2027E for HAIN (quadrant outlier)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Food Ingredients and Flavorings recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 42 transactions were recorded for this industry; 15 are shown. 27 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 18 × deal value unit unresolved; 29 × no evidence record; 5 × divestiture roles reassigned. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 489 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

More coverage in Consumer Staples

Want this analysis for a company in Food Ingredients and Flavorings?

Company valuation reports run the same method against a single business — public or private.

Get your reportTalk to advisory